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Innovations
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Soporific Science
finities 10 and 50 times greater than the number of awakenings during
the night. These data were collectedAmbien and Sonata, respectively. It
to find a suitable dose of indiplon tois this receptor specificity that is
We spend approximately one-third
of our lives sleeping, yet a definite
understanding of the purpose of
sleep remains elusive. Sleep is no utilize in phase III clinical studies.thought to minimize the unwanted
doubt critical to a person’s well be- There was a clear dose response onside effects associated with the ben-
ing, whether or not the detailed all parameters, and all doses signifi-zodiazepine compounds.
mechanisms linking health and cantly improved the latency to per-In order to address all forms of
sleep are known. Unfortunately, sistent sleep, the number of awak-sleeplessness—sleep initiation,
51% of the U.S. adult population enings, and the number of patientsnight awakenings, and total sleep
complains of insomnia, according to sleeping longer than seven hours.maintenance—Neurocrine has de-
the National Sleep Foundation’s For these titration studies, no next-veloped two formulations of in-
2001 Sleep in America Poll. In fact, day residual sedation effects werediplon, an immediate release (IR) for-
nearly three out of ten Americans found with indiplon IR or MR, ac-mulation and a modified release
(29%) say they experience insomnia cording to tests such as the Digit(MR) formulation. Since indiplon has
every night or almost every night. Symbol Substitution Test, Symbola short half-life, it is rapidly cleared
And while there is a range of avail- Copy Test, and Visual Analog Scalefrom the bloodstream and will theo-
able sleep aids for insomnia suffer- of Sleepiness, as well as the pa-retically not impair a patient the next
ers, many come with a range of tient’s own assessment.day. This scenario works well for
problems. From over-the-counter Indiplon is the lead clinical devel-those having trouble falling asleep.
sleeping pills to prescription drugs, opment for Neurocrine Biosciences,However, for those who awake after
often the medicines simply do not Inc. in San Diego, CA. Neurocrineonly a few hours, the modified re-
induce sleep, or if sleep is success- will be conducting five phase III clini-
fully provided, the next-day residual cal trials with indiplon-IR as well as
51% of the U.S. adulteffects are frequently burdensome. three phase III trials with indiplon-
MR administered to approximatelyThose suffering from transient or population complains of
chronic insomnia can hope for main- 3500 patients overall. These trialsinsomnia, according totained sleep without next-day im- will support market registration of
the National Sleep Foun-pairment provided by indiplon, a indiplon for short-term and long-
term treatment in adult and elderlynew compound with an anticipated dation’s 2001 Sleep in
approval from the Food and Drug patients with primary (chronic) orAmerica Poll.Administration (FDA) after submis- transient insomnia. The clinical pro-
sion in late 2003. Produced by Neu- gram for indiplon will be one of the
rocrine Biosciences, this novel ther- largest and most comprehensive
lease form provides the initial doseapeutic has successfully advanced evaluations of a therapeutic agent
followed by another dose four hoursthrough phase I and II clinical trials, for insomnia, encompassing well over
later. This timed-release protocoland since November 2001 it has 5000 patients and addressing the
has been shown to be effective forbeen progressing through phase III multiple needs of patients who suf-
maintaining sleep throughout thetrials. fer with insomnia.
night in phase II patients. AnotherIndiplon is a nonbenzodiazipine Founded in 1992 by Wylie Vale,
phase II study in which the drug wassleep-promoting drug that enhan- Ph.D. and Lawrence Steinman, MD,
administered in the middle of theces the action of the inhibitory neu- Neurocrine focuses primarily on
night showed that there was norotransmitter GABA. To achieve this, small molecule drug discovery and
next-day residual sedative effectindiplon acts as an agonist at spe- development for treatment of neu-
when the subjects were awakenedcific sites on the GABA-A receptor. rological and endocrine system-
four hours after dosing, while bothSimilar to the current sleep aids Am- related diseases and disorders. In
Ambien (nonbenzodiazepine) andbien and Sonata, indiplon shows addition to insomnia, Neurocrine’s
zoplicone (benzodiazepine), whichspecific binding to BZ1 or Alpha1 current projects involve therapeu-
have longer half-lives, showed sig-subtypes of the GABA-A receptor tics for anxiety, depression, malig-
nificant sedative effects.and is therefore different from the nant brain tumors and peripheral
In sleep laboratories under well-classical sedative hypnotic drugs cancers, diabetes mellitus, multiple
controlled conditions, a phase II dou-known as benzodiazepines, which sclerosis, irritable bowel syndrome,
ble-blind placebo study was initiateddo not discriminate between recep- eating disorders, pain, prostate can-
using a polysomnography, whichtor subtypes. However, the specific cer, obesity, and female health dis-
measures the time to sleep, the dura-binding of indiplon is much more po- orders. With its 250 employees, the
company has sixteen programs intent for this ligand, with binding af- tion of sleep, sleep efficiency, and
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various stages of research and de- and clinical biology of immunologi-
cal diseases of the central nervousvelopment, including five in clinical
system, with a focus on understand-development.
ing the mechanism of action of theAccording to published reports,
altered peptide ligand (APL) ap-the phase I and II trials for indiplon
proach for multiple sclerosis andproved to be flawless. With such a
other autoimmune diseases such asdisplay of potential, indiplon did not
type I juvenile diabetes. Progress isgo unnoticed. In December 2002, 13
continuing through phase II clinicalmonths after the start of the phase
trials in both the multiple sclerosisIII trials for indiplon, Neurocrine an-
and diabetes compounds.nounced a deal worth up to $400
Of course, Neurocrine’s hopemillion to share rights of indiplon
would be that more of their re-with Pfizer, the world’s largest phar-
searched therapeutics follow a clini-maceutical company. Pfizer agreed
cal trials path like that of indiplon. Ato pay Neurocrine $100 million up-
patent for indiplon and the use offront and up to $300 million in mile-
indiplon was issued in June, 2002:stone payments in return for exclu-
U.S. Patent No. 6,544,621. In earlysive rights to distribute the sleeping
April of 2003, Neurocrine announcedpill outside the United States and
they had received the issuance ofshared rights in the more lucrative
U.S. Patent No. 6,544,999 coveringU.S. market.
a stable polymorph of indiplon. ThisThis deal was one of the largest
patent will provide Neurocrine within 2002 between a biotech and a
patent protection for this crystallinepharmaceutical company. According
form of indiplon. With further patentsto Michael King of Banc of America
to come, this potential insomniaSecurities, indiplon could reach
compound will be protected for 17$700 million in sales by 2007, about
years on many fronts. As part of thethree years after its anticipated FDA
collaboration with Pfizer, a 200-per-
approval in late 2004. “Big pharma
son sales force will be established
would like to do more deals like this,”
to reach psychiatrists and sleep
said King, “but there aren’t too many specialists. Once the NDA (New
exciting products out there to li- Drug Application) is submitted, this
cense. Neurocrine was one of the marketing force will promote the an-
last really good ones around, and tidepressant Zoloft to U.S. psychia-
they could have had their pick of trists. With this approach, Neuro-
anyone they wanted.” (San Diego crine will establish a relationship
Union-Tribune, December 20, 2002). with psychiatrists prior to the antici-
The expertise of Neurocrine’s two pated launch of indiplon, after which
founders furnished the company Neurocrine will copromote indiplon
with a strong 2-fold research plat- with Pfizer.
form. Dr. Wylie Vale and his col- “The events of 2002 were signifi-
leagues at the Salk Institute were the cant milestones for Neurocrine, and
first to identify and sequence the as a result the company is moving
corticotropin releasing factor (CRF), closer to realizing our strategic ob-
a neurotransmitter in the brain, jective of becoming a fully inte-
which plays a critical role in coordi- grated pharmaceutical company,”
nating the body’s overall responses reported Paul Hawran, Executive
to stress. Early phase I studies have Vice President and Chief Financial
shown that CRF receptor antagonist Officer for Neurocrine Biosciences
compounds for the treatment of de- in a PR Wire report of February,
pression and anxiety are rapidly 2003. No doubt, the progress of in-
absorbed with no apparent safety diplon has helped Neurocrine realize
issues to preclude clinical trial ad- some of its goals and is a glimmer
vancement. Additional clinical indi- of hope for the innovative but often
cations for CRF1 receptor antago- financially tenuous biotech com-
nists include treatment for irritable panies.
bowel syndrome, inflammatory pain,
Chemistry & Biology invites yourstroke, and other neurodegenera-
comments on this topic. Pleasetive diseases.
write to the editors at chembiol@The second thrust of Neurocrine’s
cell.com.research was established by Dr.
Lawrence Steinman of the Stanford Nicole Ballew is a freelance science writer
University School of Medicine. Stein- based in Lebanon, NH (nballew@hotmail.
com).man’s expertise encompasses basic
